Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Exploring neuroinflammation as a potential avenue to improve the clinical efficacy of opioids|
|Citation:||Expert Review of Neurotherapeutics, 2012; 12(11):1311-1324|
|Publisher:||Expert Reviews Ltd.|
|Jacob Thomas and Mark R Hutchinson|
|Abstract:||Opioids are an extremely important part of medical practice, and for thousands of years, continued to provide relief from severe acute and chronic pain. Intriguingly, use of opioids activates endogenous counter-regulatory mechanisms resulting in increased sensitivity to noxious stimuli and the requirement for higher doses of opioids to reach an effective level of analgesia. Until recently, research into the counter regulators of opioid-induced analgesia had been focused on the role of neuronal receptors where the beneficial and detrimental actions of opioids were thought to be inseparable. It is now apparent from molecular and rodent data that opioids have non-neuronal, nonclassic, nonstereoselective sites of action. At these newly recognized sites, opioid activity significantly modifies the pharmacodynamics of opioids by eliciting proinflammatory reactivity from immunocompetent cells of the CNS. This review will examine the nonclassic actions of opioids specifically appreciating the actions of the released immune products.|
|Keywords:||analgesia; central immune; chemokine; CNS; cytokine; glia; nonstereoselectivity; opioid; tolerance|
|Rights:||Copyright status unknown|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.